This inventor holds 2 USPTO granted patents. Top assignee: Wakunaga Seiyaku Kabushiki Kaisha. Active years: 1988-1989.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Hiroshima, JP (1988)
- Koda, JP (1989)
Company Filing History:
Years Active: 1988-1989
Title: Shunsou Hatono: Innovator in Bile Acid Derivatives
Introduction
Shunsou Hatono is a notable inventor based in Hiroshima, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of bile acid derivatives. With a total of 2 patents to his name, his work focuses on compounds that exhibit potential therapeutic benefits.
Latest Patents
Hatono's latest patents include innovative bile acid derivatives that demonstrate carcinostatic activity. One of his patents describes a bile acid derivative characterized by a specific formula, which includes various functional groups that contribute to its low toxicity and effectiveness as a carcinostatic agent. Another patent outlines a similar bile acid derivative, detailing the production process and its potential applications in cancer treatment.
Career Highlights
Shunsou Hatono is currently employed at Wakunaga Seiyaku Kabushiki Kaisha, a company known for its commitment to health and wellness through innovative pharmaceutical products. His work at the company has allowed him to focus on the development of compounds that can significantly impact cancer treatment.
Collaborations
Throughout his career, Hatono has collaborated with esteemed colleagues such as Akira Yazaki and Susumu Yoshida. These partnerships have fostered a collaborative environment that enhances the research and development of new medicinal compounds.
Conclusion
Shunsou Hatono's contributions to the field of bile acid derivatives highlight his innovative spirit and dedication to improving cancer treatment options. His work continues to inspire advancements in medicinal chemistry and offers hope for future therapeutic developments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
